Therapeutic rationale of targeting BCG and immune checkpoints in non-muscle-invasive bladder cancer: Is this the Future?

Urol Oncol. 2019 Jun;37(6):343-345. doi: 10.1016/j.urolonc.2019.02.001. Epub 2019 Feb 28.

Authors

Andrea K Lindner¹, Tobias Klatte², Eva Comperat³, Isabel Heidegger¹, Renate Pichler⁴

Affiliations

¹ Medical University Innsbruck, Department of Urology, Innsbruck, Austria.
² Department of Urology, The Royal Bournemouth and Christchurch Hospitals, Bournemouth, UK.
³ Department of Pathology, Hospital Tenon, Sorbonne University, Paris, France.
⁴ Medical University Innsbruck, Department of Urology, Innsbruck, Austria. Electronic address: Renate.Pichler@i-med.ac.at.

PMID: 30826167
DOI: 10.1016/j.urolonc.2019.02.001

No abstract available

Publication types

Letter
Comment

MeSH terms

BCG Vaccine
Carcinoma, Transitional Cell*
Humans
Immunotherapy
Mycobacterium bovis*
Urinary Bladder Neoplasms*

Substances

BCG Vaccine